Switch to:
Valeant Pharmaceuticals International Inc (NYSE:VRX)
Research and Development
$382 Mil (TTM As of Mar. 2016)

This is the expense the company spent on research and development. Valeant Pharmaceuticals International Inc's research and development for the three months ended in Mar. 2016 was $103 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2016 was $382 Mil.


Definition

This is the expense the company spent on research and development.

Valeant Pharmaceuticals International Inc Research & Development for the trailing twelve months (TTM) ended in Mar. 2016 was 81.1 (Jun. 2015 ) + 101.6 (Sep. 2015 ) + 95.9 (Dec. 2015 ) + 103.1 (Mar. 2016 ) = $382 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Valeant Pharmaceuticals International Inc Annual Data

Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15
Research & Development 9511893121158175269157246334

Valeant Pharmaceuticals International Inc Quarterly Data

Dec13Mar14Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16
Research & Development 6061675959568110296103
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK